Aytu BioScience

Aytu BioScience is a commercial-stage biopharmaceutical company with a mission to identify, acquire, and commercialize novel therapeutics for patients with high unmet medical needs. Its strategy centers on building a diversified portfolio of commercial products and late-stage development candidates, primarily in rare pediatric and central nervous system disorders. The company generates revenue from its commercial assets while advancing its pipeline to drive future growth. Aytu's focus on underserved markets aims to create significant value for patients and shareholders.

Aytu's core model is a commercial and development platform focused on identifying, acquiring, and commercializing novel therapeutics, particularly in rare pediatric and CNS disorders, rather than a proprietary discovery technology.

Aytu competes in segmented markets against large pharma (e.g., Takeda in ADHD) and specialty pharma peers. Its differentiation lies in unique formulations (ODTs), focus on rare pediatric indications, and tamper-resistant OTC technology, allowing it to target specific niches rather than competing head-on in broad markets.